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Abstract
Background: Selective degeneration of medium spiny neurons and preservation of medium sized aspiny interneurons in
striatum has been implicated in excitotoxicity and pathophysiology of Huntington’s disease (HD). However, the molecular
mechanism for the selective sparing of medium sized aspiny neurons and vulnerability of projection neurons is still elusive.
The pathological characteristic of HD is an extensive reduction of the striatal mass, affecting caudate putamen. Somatostatin
(SST) positive neurons are selectively spared in HD and Quinolinic acid/N-methyl-D-aspartic acid induced excitotoxicity,
mimic the model of HD. SST plays neuroprotective role in excitotoxicity and the biological effects of SST are mediated by
five somatostatin receptor subtypes (SSTR1-5).
Methods and Findings: To delineate subtype selective biological responses we have here investigated changes in SSTR1
and 5 double knockout mice brain and compared with HD transgenic mouse model (R6/2). Our study revealed significant
loss of dopamine and cAMP regulated phosphoprotein of 32 kDa (DARPP-32) and comparable changes in SST, N-methyl-D-
aspartic acid receptors subtypes, calbindin and brain nitric oxide synthase expression as well as in key signaling proteins
including calpain, phospho-extracellular-signal-regulated kinases1/2, synapsin-IIa, protein kinase C-a and calcineurin in
SSTR1/5
2/2 and R6/2 mice. Conversely, the expression of somatostatin receptor subtypes, enkephalin and phosphatidy-
linositol 3-kinases were strain specific. SSTR1/5 appears to be important in regulating NMDARs, DARPP-32 and signaling
molecules in similar fashion as seen in HD transgenic mice.
Conclusions: This is the first comprehensive description of disease related changes upon ablation of G- protein coupled
receptor gene. Our results indicate that SST and SSTRs might play an important role in regulation of neurodegeneration and
targeting this pathway can provide a novel insight in understanding the pathophysiology of Huntington’s disease.
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Introduction
Huntington’s disease (HD) is an inherited autosomal dominant
neurodegenerative disorder caused by mutation in the huntingtin
(Htt) gene and characterized by progressive chorea and impaired
cognitive function [1,2]. Genetic abnormality of expanded
polyglutamine repeat sequence is confined in the coding region
of a gene IT15 located on chromosome 4 encoding the Htt protein
[3,4]. The length of CAG repeat is one of the factors that plays an
important role in the onset of HD symptoms [5,6]. Pathological
characteristics of the disease are the intranuclear inclusion of
mutated Htt and neostriatum atrophy and gliosis.
In addition to genetic mutation and histopathological hallmarks,
the critical determinant of HD is the degeneration of medium size
spiny neurons (MSNs) expressing c-aminobutyric acid (c-GABA),
N-methyl-D-aspartic acid receptors (NMDARs) and dopamine
and cAMP regulated phosphoprotein of 32 kDa (DARPP-32). In
contrast, in striatum, a subset of neuronal population consisting of
medium sized aspiny interneurons positive to somatostatin (SST),
neuropeptide Y (NPY) and nicotinamide adenine dinucleotide
phosphate-diaphorase (NADPH-d)/brain nitric oxide synthase
(bNOS) are selectively spared [7,8]. In addition, the expression of
calbindin D-28K is increased in HD patients, transgenic mouse
models and quinolinic acid (QUIN)-induced excitotoxicity
[9,10,11]. Activation of NMDARs in striatum mimics the
pathological, neurochemical and behavioral changes of HD [12].
Furthermore, the analysis of HD patient’s postmortem brain
reveals the degeneration of NMDAR-positive neurons and
association with the pathogenesis in HD [13,14]. NMDARs are
composed of two subunits of NR1 and two subunits of NR2A,
NR2B or NR2C [15,16]. Previous studies have shown enhanced
NMDAR-mediated toxicity in cells expressing mutated Htt as well
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e24467as in HD mouse models [17,18]. Recently, the functional
importance of NMDARs emerged from a study describing the
role of NMDAR antagonist memantine to block the nuclear
inclusion of Htt in yeast artificial chromosome (YAC) mice [19].
These data suggest that NMDARs play an important role in HD
and may contribute to neuronal loss.
NMDA replicate the neurophathological features of HD and
have been used as models of the disease [20,21]. In the striatum of
experimental mice, medium-sized aspiny interneurons expressing
SST, NPY and NADPH-d/bNOS are selectively resistant to
QUIN-induced excitotoxicity. Similarly, such interneurons are
relatively well spared observations in the brains of HD patients
[19,21,22,23,24,25,26]. Previous studies have also shown increased
SST secretion and gene expression in HD brain and NMDA/
QUIN-induced excitotoxicity [21,23,27]. In support of the selective
preservation of interneurons, it was argued that these neurons lack
NMDARs [28]. In contrast, several recent studies have shown the
presence of NMDARs in SST/NPY/NOS positive neurons in
striatum of rat brain and cultured striatal neurons [4,29,30]. Most
importantly, we have recently shown that immunoblockade of SST
by using antisense oligoneucleotides and immunoneutralization of
released SST by using SST specific antibodies potentiate neuronal
loss in QUIN/NMDA-induced excitotoxicity in cultured striatal
neurons, including NPY, NADPH-d and bNOS positive neurons
[31]. Furthermore, selective sparing of SST positive neurons in
bNOS knockout mice suggests that the presence of SST is essential
for the survival of interneurons [32].
The presence of SST in the central and peripheral nervous
system is associated with several physiological functions, which are
attributed to different receptor subtypes, namely somatostatin
receptor 1–5 (SSTR1-5), which are members of G-protein coupled
receptor (GPCR) family. All five SSTR subtypes display
overlapping distribution in different parts of brain and importantly
couple to Gi protein and inhibit cAMP in a pertussis toxin sensitive
manner. SSTRs are involved in the regulation of ion channels;
inhibition of Ca
2+ and activation of K
+ channels involved in the
release of several neurotransmitters and modulation of neuro-
transmission [33]. These functional properties of SSTR subtypes
can be further enhanced by interaction with members of their own
family as well as other GPCRs, including dopamine and opioid
receptors via heterodimerization [34,35,36,37]. Widespread dis-
tribution of SSTRs in CNS is involved in various neurological
diseases such as Huntington’s disease (HD), Alzheimer’s disease
(AD), Parkinson’s disease (PD), epilepsy, HIV encephalitis,
dementia and psychiatric disorders, including schizophrenia
[22,38,39,40,41,42]. These studies cumulatively suggest the critical
and pivotal role of SSTR subtypes in neurodegenerative diseases.
We recently observed that the knock-down of SSTR 1 and
SSTR 5 using antisense oligonucleotides accelerated neuronal
death upon NMDA treatment in cultured striatal neurons
(unpublished observations). Accordingly, in an attempt to elucidate
the possible functions of SSTR1 and 5, the present study was
undertaken to determine the expression of NMDARs, DARPP-32,
calbindin, bNOS/SST and SSTRs in striatum of R6/2 and
SSTR1/5
2/2mice. In addition, we also studied the downstream
signaling cascades including calcineurin, calpain, PKC-a, ERK1/
2, synapsin-IIa and enkephalin associated in the process of
neurodegeneration in HD pathology as well as in experimental
models of the disease. In the present study, for the first time, we
describe that the SSTR1/5 complex is a critical regulator of
NMDARs, DARPP-32 and downstream signaling cascades
normally seen in R6/2 transgenic mice. Importantly, this study
revealed that SSTR1/5
2/2 mice mimic neuro-and biochemical
changes of presymptomatic HD transgenic mice.
Results
Decreased DARPP-32 expression and increased Calbindin
D-28K expression in striatum of SSTR1/5
2/2 mice and R6/
2 mice brain
Neuronal population in striatum is largely composed of medium
sized projection neurons, which are positive for DARPP-32 and
constitute 85% of total neuronal population. Several previous
studies have shown significant loss of DARPP-32 like immunore-
activity in HD patients and/or in experimental models of disease
[43,44]. Accordingly, here we examined the DARPP-32 like
immunoreactivity using immunohistochemical and Western blot
analysis in R6/2 and SSTR1/5
2/2 as well as respective wt mice
brains. As illustrated in Figure 1a, consistent with previous studies,
a marked decrease in signal intensity of DARPP-32 was observed
in R6/2 when compared to wt mice. Like R6/2 mice, a similar
decrease in DARPP-32 like immunoreactivity was observed in
SSTR1/5
2/2 when compared to wt mice. DARPP-32 like
immunoreactivity is mostly expressed as cytoplasmic protein.
Consistent with our immunocytochemistry data, Western blot
analysis showed a significant decrease in DARPP-32 expression in
comparison to wt in the brains of both R6/2 and SSTR1/5
2/2
mice (Figure 1b).
Similar to DARPP-32, calbindin D-28K immunoreactivity was
detected in the striatum and has been used as an index of MSN. As
illustrated in Figure 1c, increased expression of calbindin-like
immunoreactivity was observed in R6/2 and SSTR1/5
2/2 when
compared to wt mice. Western blot analysis showed consistent
results as seen in immunohistochemistry with increased expression
of calbindin in striatum of R6/2 and SSTR1/5
2/2 mice
(Figure 1c).
SST and bNOS positive neurons are selectively spared in
striatum of R6/2 and SSTR1/5
2/2 mice
Previous studies have shown that medium-sized aspiny
interneurons positive for bNOS/ NADPH-d also co-express SST
and NPY and are selectively preserved in HD patients as well as
experimental models of disease [7,8]. Accordingly, we determined
the expression of bNOS and SST-positive neurons in striatum of
R6/2 and SSTR1/5
2/2 mice brain. As shown in Figure 2a,
bNOS immunoreactivity was observed in sparsely distributed
neurons all over the striatum with arborizing neuronal processes
without discernable changes in R6/2 and SSTR1/5
2/2 mice
when compared to wt mice. In addition, Western blot analysis also
revealed no significant changes in bNOS expression levels in R6/2
and SSTR1/5
2/2 mice in comparison to their counterpart wt.A s
shown in Figure 2b, the neuronal population exhibiting SST like
immunoreactivity was comparable in R6/2 and SSTR1/5
2/2
mice using immunohistochemistry and Western blot analysis. As
shown in Figure 2c, further quantitative analysis revealed
comparable changes in bNOS and SST positive neurons in R6/
2 and SSTR1/5
2/2 mice as well as in comparison to wt. R6/2
transgenic mice exhibited 14 and 8% loss of bNOS and SST
positive neurons, respectively. Conversely, SSTR1/5
2/2 mice
showed 15 and 3% loss of bNOS and SST positive neurons
respectively, not significantly different from wt mice.
Expression of NMDA receptor subtypes in the striatum of
SSTR1/5
2/2 and R6/2 mice
The roleof activated NMDARs in degeneration of medium spiny
neurons in HD as well as in excitotoxicity is indisputable. Several
previous studies have shown the activation of NMDAR subtypes in
the brain of R6/2 transgenic mice [18]. We sought to determine
Somatostatin Receptor 1/5 Knockout and R6/2 Mice
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2/2 mice exhibit comparable cellular
distribution pattern in NMDAR subunits and determined the
expression levels of NR1, NR2A and NR2B using immunohisto-
chemistry and Western blot analysis. As shown in Figure 3a, in wt
mice brain NR1-like immunoreactivity in striatal neurons was
confined to the cell membranes, as well as, intracellularly.
Additionally, NR1-like immunoreactivity was also seen in nerve
fibers. In comparison to wt, R6/2 mice brain displayed strong NR1
immunoreactivity that was restricted to cell membrane. Consistent
with immunohistochemistry, increased receptor expression was
observed in striatal tissue lysate prepared from R6/2 mice in
comparison to wt. Similar pattern of NR-1 immunoreactivity was
observed in SSTR1/5
2/2 mice in comparison to wt using
immunohistochemistry and Western blot analysis (Figure 3a).
Similar to the NR1 expression, NR2A subunit expression was
increased in R6/2 and SSTR1/5
2/2 mice when compared to
respective wt (Figure 3b). Interestingly, NR2A immunoreactivity
expressed at cell surface in R6/2 mice in comparison to SSTR1/
5
2/2 mice where receptor immunoreactivity was markedly
intracellular. Western blot analysis revealed enhanced NR2A
expression in SSTR1/5
2/2 mice in comparison to R6/2 mice as
well as respective wt. In comparison to NR1 or NR2A expression,
R6/2 and SSTR1/5
2/2 mice exhibited the loss of NR2B
immunoreactivity. The loss of NR2B was to a greater extent in
R6/2 brain than SSTR1/5
2/2 mice (Figure 3c). The distributional
patternof NR2B-like immunoreactivity was significantly differentin
Figure 1. Representative low- and high-magnification photomicrogrpahs depicting comparative distribution of DARPP-32
immunoreactivity in striatum of R6/2 and SSTR1/5
2/2 mice. DARPP-32 like immunoreactivity was lost in striatum of R6/2 and SSTR1/5
2/2
mice, respectively (a). Comparable decreased expression of DARPP-32 (32 kDa) in R6/2 and SSTR1/5
2/2 mice was also seen in Western blot analysis
(b). Calbindin like immunoreactivity was found to be increased in both R6/2 and SSTR1/5
2/2 mice compared to respective wt mice (c upper panel).
Increased calbindin (28 kDa) expression was further confirmed with Western blot analysis (c bottom panel). Data presented as mean 6 SD for
Western blot analysis (SSTR1/5
2/2, n=5 and R6/2 mice, n=3) in comparison to wt mice brain,***P,0.001 and *P,0.05. Scale bar=150 mm and
20 mm upper and bottom panel a,2 0mm panel c and 5 mm for inset.
doi:10.1371/journal.pone.0024467.g001
Somatostatin Receptor 1/5 Knockout and R6/2 Mice
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2/2mousestriatum.AsillustratedinFigure3c,
in R6/2 mice, NR2B in striatal neurons was expressed at cell
surface, whereas in SSTR1/5
2/2 mice, receptor-like immunore-
activity was present intracellularly. These data collectively provide
comparable changes in NMDAR subunits in R6/2 and SSTR1/
5
2/2 mice with a distinct distribution pattern. As illustrated in
Figure 3d, quantitative analysis revealed that R6/2 and SSTR1/
5
2/2 mice displayed 10 and 16% increase in neuronal population
positive to NR1 whereas 15 and 12% increase was observed in
NR2A. In contrast, neuronal population expressing NR2B declined
by 21% in R6/2 mice without any significant changes in SSTR1/
5
2/2 mice brain when compared to wt mice.
Figure 2. Comparative immunohistochemical localization of bNOS and SST in striatum of R6/2 and SSTR1/5
2/2 mice. The expression
level of bNOS (a upper panel) was comparable in both strains. Furthermore, Western blot analysis revealed no significant changes in bNOS
(160 kDa) expression (a bottom panel). As shown in upper panel b expression of SST in both the strains was comparable. Western blot analysis
reveals no change in expression of SST (28 kDa) in both the strains (b bottom panel) when compared to respective wt. Histogram represent
quantitative analysis of bNOS and SST positive neurons (c). Data presented as mean 6 SD (SSTR1/5
2/2, n=5 and R6/2 mice, n=3) in comparison to
wt mice brain. Scale bar=20 mm panel a and b and 5 mm for inset.
doi:10.1371/journal.pone.0024467.g002
Somatostatin Receptor 1/5 Knockout and R6/2 Mice
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SSTR1/5
2/2 and R6/2 mice
In our recent study, we have shown the expression of SSTRs in
both MSNs and interneurons [45]. We have recently shown the
receptor specific changes in cortical brain region of SSTR-
5
2/2mice [46]. Here we describe the comparative distribution
pattern of SSTR subtypes in striatal brain regions of R6/2 and
SSTR1/5
2/2 mice. In both cases, SSTRs like immunoreactivity
was observed in medium-sized projection neurons, as well as in
medium-sized aspiny interneurons in a receptor-specific manner.
As shown in Figure 4, SSTR1-like immunoreactivity was increased
in R6/2 mice in comparison to wt, as expected in SSTR1/5
2/2
Figure 3. Representative photomicrographs illustrating distribution of NMDAR subtypes expression in striatum of R6/2 and SSTR1/
5
2/2 mice. Comprarable distribution pattern of NR1 (a), NR2A (b) and NR2B (c) was seen between R6/2 mice and SSTR1/5
2/2 mice. Quantitaive
analysis of receptor immunoreactivity was accomplished using Western blot analysis. Note the increased expression of NR1 (120 kDa)
immunoreactivity (a upper panel) and expression by Western blot (a lower panel) in R6/2 and SSTR1/5
2/2 mice. NR2A (180 kDa) expression was
increased in R6/2 and SSTR1/5
2/2 mice (b). Decreased expression of NR2B (190 kDa) was seen in R6/2 mice whereas no significant changes in SSTR1/
5
2/2 mice when compared to wt mice (c). Note cytosolic accumulation of NR2A and NR2B in SSTR1/5
2/2 mice and membrane expression in R6/2
mice. Percentage changes in NMDARs positive neurons in R6/2, SSTR1/5
2/2 mice and wt mice are shown in panel (d). Data presented as mean 6 SD
for Western blot analysis (SSTR1/5
2/2, n=5 and R6/2 mice, n=3) in comparison to wt mice brain, *P,0.05, ** P,0.01. Scale bar=20 mm panel a–c
and 5 mm for inset.
doi:10.1371/journal.pone.0024467.g003
Somatostatin Receptor 1/5 Knockout and R6/2 Mice
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receptor-like immunoreactivity (Figure 4a). Like SSTR1, in R6/2
and SSTR1/5
2/2 mice striatum, SSTR2 like immunoreactivity
was increased as determined by immunohistochemistry and
Western blot analysis (Figure 4b). Interestingly, SSTR3 like
immunoreactivity in R6/2 and SSTR1/5
2/2 mice exhibited
distinct distribution pattern. As illustrated in Figure 4c, increased
expression of SSTR3 was seen in R6/2 mice in comparison to wt,
whereas SSTR1/5
2/2 displayed significant loss in SSTR3 likes
immunoreactivity when compared with wt. Conversely, SSTR4-
like immunoreactivity was comparable in both R6/2 and SSTR1/
5
2/2 mice without any discernable changes (Figure 4d). R6/2
transgenic mice exhibited increased expression of SSTR5 like
immunoreactivity when compared with wt (Figure 4e). Although
no SSTR5 expression was seen in SSTR1/5
2/2 mice, SSTR5 like
receptor expression was well expressed in wt. As illustrated in
supplemental Figure S1, quantitative analysis of SSTR subtypes
indicates receptor specific changes in R6/2 and SSTR1/5
2/2.I n
R6/2 transgenic mice SSTR1, SSTR2, SSTR3 and SSTR5
positive immunoreactive neurons were increased by 25, 18, 19 and
17%, respectively, in comparison to wt. Conversely, SSTR4
positive neurons were not changed significantly in R6/2 and
SSTR1/5
2/2 in comparison to wt. However, in SSTR1/5
2/2
mice SSTR2-positive neurons increased by 25%, whereas SSTR3
positive neurons declined by 38% when compared to wt.
Comparable changes in signaling cascades in striatum of
SSTR1/5
2/2 and R6/2 mice
The physiological response of neurons upon activation or
inhibition of GPCR or ionotropic receptors is intimately associated
with the modulation of signaling pathways. Whether the ablation
of SSTR modulates signaling cascades similar to the model of
neurodegenerative disease has not been studied yet. Several
previous studies have shown significant changes in mitogen
activated protein kinases (MAPK); extracellular regulated kinase
(ERK1/2) and several other key regulators associated with
neuronal degeneration and pathogenesis of neurodegenerative
diseases. To ascertain the underlying mechanism and functional
consequences of the changes seen in SSTR and NMDAR subtypes
here we determined the expression levels of pERK1/2, PKC-a,
PI3K, calcineurin, calpain, synapsin-IIa, and enkephalin in
striatum of R6/2 and SSTR1/5
2/2 mice brain by Western blot
analysis. As shown in Figure S2a, the expression levels of pERK1/
2 were not altered in R6/2 mice whereas the status of pERK1/2
was increased in SSTR1/5
2/2 mice but not significantly when
compared to wt. The expression level of cell survival pathway
PI3K was increased in SSTR1/5
2/2 mice, whereas, it decreased
significantly in R6/2 transgenic mice (Supplemental Figure S2b).
In contrast, decreased expression of PKC-a (Figure S2c) was
observed in SSTR1/5
2/2 mice and R6/2 mice when compared
to wt.
Previous studies have shown that the inhibitors of calcineurin
accelerate HD neurological phenotype in R6/2 mice [47].
Accordingly, we determined the expression levels of calcineurin
in R6/2 and SSTR1/5
2/2 mouse brains. As illustrated in
Figure 5a, calcineurin expression decreased in R6/2 and
SSTR1/5
2/2 mice, when compared to wt mice. Studies using
YAC transgenic mice models have shown increased calpain
expression, which is involved in neuronal apoptosis [48]. However,
no data is presently available for calpain expression in R6/2 mice.
As shown in Figure 5b, increased expression of calpain in R6/2
mice as well as in SSTR1/5
2/2 mice was observed. Consistent
with previous studies, these data strongly suggest the possible
interaction between activation of NMDARs and increased
expression of calpain in YAC and R6/2 transgenic mice.
Decreased expression of synapsin-IIa mRNA in striatum of R6/
2 mice without significant changes in protein expression has been
described earlier [43]. In further extension to our study, we next
determined the expression level of synapsin-IIa and enkephalin in
striatum of R6/2 and SSTR1/5
2/2 mice and compared with wt
using Western blot analysis. As shown in Figure 5c, synapsin-IIa
expression was increased in both R6/2 and SSTR1/5
2/2 mice,
whereas, no significant change in enkephalin protein expression
was observed in R6/2. However, increased expression was seen in
SSTR1/5
2/2 mice striatum in comparison to wt (Figure 5d).
In HD transgenic mice, namely YAC and R6/2, increased
apoptosis has been described in brain due to the toxic effect of
mutated Htt [49]. Here we determined whether occurrence of
apoptosis is comparable in R6/2 and SSTR1/5
2/2 mice using
Hoechst 33258 staining. As shown in Figure 5e, in the absence of
SSTR1/5 no apoptosis was observed. In comparison, R6/2 mice
exhibited increased number of apoptotic cells when compared to
their respective wt. These data strongly suggest that lack of
SSTR1/5 does not induce excitotoxicity and the changes seen in
several markers might be associated with the physiological and
pharmacological effects of SSTR subtypes.
Discussion
Receptor specific ablation of SSTR subtypes have shown
behavioral changes, impaired cognitive function, loss of analgesic
effect and sustained pain in a receptor-specific manner [50,51].
Whether SSTR ko or any other GPCRs ko mice mimic the
neurochemical changes similar to the neurodegenerative disorders
has not been studied yet. In the present study, we compared the
expression levels of key molecular markers that exert a
determining role in the pathogenesis of HD in SSTR1/5
2/2
and R6/2 mice striatum. We demonstrate that, SSTR1/5
2/2 and
R6/2 mice display comparable changes in distribution pattern of
SST, NMDA receptor (NR1, NR2A and NR2B), DARPP-32,
calbindin and bNOS, as well as the downstream signaling
pathways including pERK1/2, calpain, synapsin IIa, PKC-a,
and calcineurin in striatum. In contrast, SSTR subtypes,
enkephalin, and PI3K are modulated in strain specific manner.
This is the first comprehensive description showing comparable
neurochemical and biochemical changes in a transgenic model of
HD and SSTR1/5
2/2 mice brains.
The most coherent finding in HD pathology as well as in
transgenic mice is the loss of DARPP-32 [43]. Consistent with this
study, we describe comparable changes in DARPP-32 like
immunoreactivity in R6/2 and SSTR1/5
2/2 mice, exhibiting
.60% loss of DARPP-32. For the first time, we have
demonstrated a similar pattern of DARPP-32 loss in the striatum
of SSTR1/5 ablated mice and HD transgenic mice R6/2
indicating that SSTRs might be involved in regulation of
DARPP-32. The DARPP-32 mediated downstream signaling
pathway is modulated by dopamine receptors (DRs), another
prominent member of GPCR family [52,53]. SSTRs share ,30%
structural homology with DRs and constitute functional hetero-
dimers with distinct pharmacological properties and enhanced
signaling [36,54]. In agreement with this information, SSTRs,
directly or indirectly, via interaction with DR, may modulate
DARPP-32. This concept is further strengthened by our recent
studies showing receptor- and region-specific colocalization of
DARPP-32 and DRs in rat brain [55]. DARPP-32 becomes
phosphorylated in response to the activation of D1R [43].
Conversely, D2R activation inhibits DARPP-32 phosphorylation.
Somatostatin Receptor 1/5 Knockout and R6/2 Mice
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not known. Here we provide the evidence that in the absence of
SSTR subtypes, DARPP-32 expression is decreased in striatum in
a similar manner as seen in HD brain and/or HD transgenic mice.
The loss of DARPP-32 like immunoreactivity in SSTR1/5
2/2
mice is not surprising; as previous studies have also shown that
DARPP-32
2/2 mice resemble HD mice in dopamine signaling
[43].
Consistent with the existing notion that bNOS positive neurons
are preserved in HD, the expression pattern and quantification of
bNOS positive neurons in R6/2 mice as well as SSTR1/5
2/2
mice is comparable. Similar is the pattern of SST expression in
both strains. In line with previous observations, our results further
strengthen the concept of selective preservation of medium-sized
aspiny interneurons expressing SST/b-NOS [8]. Furthermore,
our previous studies have shown that blockade of SST using
antisense oligonucleotide leads to the loss of bNOS/NADPH-d
positive neurons upon QUIN/NMDA treatment [31]. Taken
together, these results support the notion that the presence of SST
is likely responsible for the survival of aspiny interneurons in
excitotoxicity.
In HD, the activation of NMDAR is one of the leading causes of
neuronal loss, in addition to the mutation in Htt. Functional and
physiological significance of NMDARs has recently been de-
scribed in pathophysiology of HD and reported that the NMDAR
antagonist, memantine, blocks the nuclear inclusion of mutated
Htt seen in HD [19]. Furthermore, recent studies have shown the
distinct role of synaptic and extrasynaptic NMDARs in early and
late onset of HD [56,57,58]. NMDAR positive neurons are most
vulnerable in HD as well as in various mouse models of
excitotoxicity [18,59,60,61]. Cumulatively, these studies indicate
an increase NR1 and the loss of NR2B expression. However,
studies for NR2A are controversial and such discrepancies may be
due to the mouse strain used as a model. In the current study, an
increased NR1 and NR2A expression, with the loss of NR2B
immunoreactivity in both R6/2 and SSTR1/5
2/2 mice may be
linked to the neurodegeneration of MSNs, which is attributed to
an increased Ca
2+ influx. Moreover, in SSTR1/5
2/2 mice,
NR2A and NR2B immunoreactivity accumulates intracellularly
while in R6/2 both receptors are well expressed at cell surface. In
light of these results, we propose two different mechanisms for the
role in NMDAR-mediated neurotoxicity. First, the membrane
expression of NR2A and NR2B in HD transgenic mice allows
receptor interaction at cell surface, which results in excitotoxicity.
Consistent with the existing concept that NMDARs are function-
ally active in heteromeric complex, the increased cell surface
expression of NR1 and NR2A in R6/2 might be involved in
excitotoxicity through heterodimerization. In the absence of SSTR
subtypes, NMDAR trafficking might be impaired, leading to
receptor accumulation intracellularly. Whether SSTR and
NMDAR functionally interact with each other is not known and
further studies are in progress to determine this. Studies are
warranted to delineate the molecular mechanism for the
intracellular accumulation of NMDAR in SSTR1/5
2/2 mice.
Furthermore, the possibility of impaired mitochondrial function in
these processes cannot be ruled out.
The physiological response of cells upon the activation of
SSTRs is receptor specific and can display multiple effects. SSTR2
is known to inhibit Ca
2+ activated channels and increased
neuronal Ca
2+ is detrimental in excitotoxicity in vitro as well as
in HD. Our results show increased expression of SSTR2 in the
absence of SSTR1/5 and concomitantly in HD transgenic mice,
suggesting a compensatory mechanism to inhibit Ca
2+ due to
enhanced excitatory input via the activation of NMDAR. In
support, we have recently shown that SSTR2 and SSTR5
heterodimerize with significant changes in receptor pharmacolog-
ical properties as well as enhanced signaling [62]. Furthermore,
SSTR1/5
2/2 mice exhibit increased expression of D2R in
comparison to wt (unpublished observations). Since SSTR5 and
D2R functionally interact and exist in a heteromeric complex, the
increased expression of D2R in SSTR1/5
2/2 mice supports the
compensatory role in the absence of SSTR5 in vivo [36].
Increased expression of NR1 and NR2A might be linked with the
decreased expression of calcineurin and increased expression of
calpain in R6/2 and SSTR1/5
2/2 mice. Calcineurin is involved in
the phosphorylation of DARPP-32, which further regulates the cell
survival pathways. Calcineurin knockout mice show the inhibition
of motor functions, loss of synaptic plasticity, learning and memory
[63]. The loss of calcineurin expression in R6/2 and SSTR1/5
2/2
mice might correlate with the symptoms of HD. Furthermore, the
lossofcalcineurinand DARPP-32expressioncanbecorrelatedwith
the decreased expression of PKC-a. PKC-a plays a role in
regulation of membrane associated signal transduction pathways
mediated by Ca
2+ homeostasis [64]. DARPP-32 phosphorylated at
Thr34 (threonine) via PKC-a converts into protein phosphatase-1
(PPtase-1), which in turn inhibits the phosphorylated forms of
calcium response element binding protein (CREB) and leads to cell
survival [65].Alternatively,theloss ofPKC-a expression canalsobe
correlated with increased apoptosis detected in R6/2 mice.
However, decreased expression of PKC-a may also be associated
with decreased expression of DARPP-32 in R6/2 and SSTR1/
5
2/2 mice. Changes in pERK1/2 can be correlated with the
variable expression of SSTRs. Increased pERK1/2 in SSTR1/
5
2/2 mice may be due to the loss of SSTR5, which is known to
inhibit pERK1/2 and increased expression of SSTR5 in R6/2
might exert inhibitory role on pERK1/2.
Previous studies have shown increased calpain activity in HD
human brain tissue and YAC transgenic mice [48,66,67].
Increased expressions of calpain in R6/2 and SSTR1/5
2/2 mice
further suggest a role of NMDAR-mediated cell death [48].
Enkephalin primarily functions as an anti-nociceptive but is also
disrupted in early-onset of HD [68]. In agreement with previous
studies, we detected no changes in enkephalin expression in R6/2
mice [68]. However, these results contradict other findings, which
report a decrease in enkephalin expression [69]. Such discrepan-
cies may be due to the isoform of enkephalin targeted. In SSTR1/
5
2/2 mice, increased expression of enkephalin, in part, may be
indirectly due to changes in opioid receptors, since SSTRs share
40% structural homology and exhibit heterodimerization [37].
Post-mortem brains from HD patients and transgenic mice have
shown augmented apoptosis in striatum [18]. Amongst all SSTRs,
SSTR3 is the only known receptor subtype that can induce
Figure 4. Peroxidase immunohistochemistry illustrating the changes in distribution pattern of SSTR1-5 in striatum of R6/2 and
SSTR1/5
2/2 mice. SSTR1(53 kDa) like immunoreactivity increased in striatum of R6/2 mice and abolished completely in SSTR1/5
2/2 mice (a). SSTR2
(57 kDa) like immunoreactivity was increased in R6/2 and SSTR1/5
2/2 mice (b). SSTR3 (60 kDa) expression was increased in R6/2 while it decreased in
SSTR1/5
2/2 mice striatum (c). Comparable expression of SSTR4 (44 kDa) was observed in both R6/2 and SSTR1/5
2/2 mice brain (d). SSTR5 (58 kDa)
expression was selectivley higher in R6/2 mice brain than wt and receptor like immunoreactivity was not detected in SSTR1/5
2/2 mice (e). Data
presented as mean 6 SD (SSTR1/5
2/2, n=5 and R6/2 mice, n=3) in comparison to wt mice brain, *P,0.05, ** P,0.01. Scale bar=20 mm panel a–e
and 5 mm for inset.
doi:10.1371/journal.pone.0024467.g004
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R6/2 mice is associated with apoptosis in HD needs further
investigation. However, decreased SSTR3 expression in SSTR1/
5
2/2 mice may account, albeit to a lesser degree, for apoptotic cell
death in comparison to R6/2. SST via activation of SSTR
subtypes blocks Ca
2+ influx through the interference with NMDA
function. This suggests that mice lacking SSTR1/5 may cause
pronounced NMDA-induced toxicity due to the activation of
NMDA receptors in SSTR1/5
2/2 mice. This speculation is
consistent with previous studies from HD transgenic mice [18].
Furthermore, the inhibitory effect of SST on excitatory synaptic
transmission is also well established in rodent brain [33].
Previous studies have shown that presymptomatic HD mice (6–
8 weeks old R6/2 mice) not only display physiological character-
istics but also behavioral and neurochemcial changes similar to
those observed in HD [70]. These observations indicate that
SSTR1/5
2/2 might serve as a model to elucidate the role of
SSTR subtypes to characterize the neurochemcial changes in
different proteins and pathways involved in HD. SSTR5 blocks
the L-type Ca
2+ channels and may correlate with the increased
expression of SSTR5 in R6/2 mice [71]. As SSTR5 is not
predominantly expressed in mouse striatum and SSTR1 and
SSTR5 are known to form heterodimers, we speculate that the
increased expression of SSTR1 in R6/2 mice may be due to a
Figure 5. Western blot analysis demonstrating the changes in expression of calcineurin (61kDa), calpain (90 kDa), synapsin-IIa
(74 kDa) and enkephalin (55 kDa) in tissue lysate prepared from striatum R6/2 and SSTR1/5
2/2 mice. Note the loss of calcineurin in
SSTR1/5
2/2 and R6/2 mice brain striatum (a) and increased expression of calpain and synapsin-IIa (b,c). In contrast enkephalin was not changed in
R6/2 mice whereas increased in SSTR1/5
2/2 mice brain (d). Data presented as mean 6 SD (SSTR1/5
2/2, n=5 and R6/2 mice, n=3) in comparison to
wt mice brain. *P,0.05, ** P,0.01. e) Photomicrographs showing apoptosis in R6/2 and SSTR1/5
2/2 mice striatum. R6/2 transgenic mice displayed
significantly increased number of apoptotic neuronal cells in striatum when compared to wt (e panel left). Unlike R6/2 mice, only few apoptotic
neuronal cells were observed in SSTR1/5
2/2 mice (e panel right). Arrows represent surviving cells and arrowheads represent apoptotic cells. Scale
bar=20 mm.
doi:10.1371/journal.pone.0024467.g005
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potential question about the role of SSTR1 or SSTR5
independently. We did not eliminate this question from our
discussion and propose that knocking out SSTR1 or SSTR5 might
have same effect as seen in double ko mice, albeit to the lesser
degree. We have recently characterized the SSTR subtypes for
homo-and heterodimerization in detail with distinct pharmaco-
logical and enhanced functional properties [34,35,72].
Taken together, our results indicate that SST and SSTRs might
play an important neuroprotective role in neurodegenerative
diseases. Targeting this pathway can provide novel insights in
understanding the pathophysiology of neurodegenerative diseases.
This is the first study showing similar disease characteristics related
to neurochemical changes upon ablation of the GPCR gene (i.e.,
SSTRs). We here reinforced the concept that mice in the absence
of SSTR subtype might have greater susceptibility to neurode-
generative diseases as well as excitotoxicity. We propose that in
HD transgenic mice as well as in HD patient’s pharmacological
restoration and maintenance of somatostatinergic system might
serve as a beneficial therapeutic approach in treatment of HD.
Materials and Methods
Materials
Rabbit polyclonal antibodies for SSTR subtypes have been
previously characterized [42,45,73]. Mouse monoclonal antibodies
for DARPP-32 and calcineurin were purchased from BD
Biosciences (Mississauga, ON, Canada). Antibodies against
NMDAR-1, NMDAR-2A, and NMDAR-2B were obtained from
Millipore (CA, USA) and anti-calbindin D-28K from Sigma-
Aldrich (MO, USA). PKC-a, ERK1/2, synapsin-IIa and Met/Liu
enkephalin were obtained from Cell Signaling Technology (MA,
USA). The peroxidase vectastain ABC kit was purchased from
Vector Laboratories (CA, USA). Nitrocellulose Hy-bond mem-
brane and enhanced chemiluminescence (ECL) detection kit was
obtained from Amarsham Ltd. (Oakdale, ON, Canada). All other
chemicals of analytical grade were obtained from various
commercial sources.
Animals
Perfused and frozen brains from 8-week old HD (C57BL/6 X
CBA)F1(B6CBA)-TgN (HDexon1)62 (R6/2) carrying 120 +/2 5
CAG repeat expansions and [wild-type(WT)]B6CBAF1/J mice
were obtained from Jackson Laboratory (Sacramento, CA, USA).
Similarly, frozen and perfused brains from 8 weeks old SSTR1/
5
2/2 mice and wt were kindly provided by Dr. F. C. Brunicardi
(Michael E. DeBakey Department of Surgery, Baylor College of
Medicine, Houston, Texas, USA). Further details for the creation
and characterization of SSTR1/5
2/2 mice have been described in
detail previously [74]. The protocols regarding animal care were
followed in compliance with the Institute of Laboratory Animal
Resources, Commission on Life Sciences, National Research
Council. The wt and SSTR1/5
2/2 mice were housed at Baylor
college of Medicine, Houston, Texas, USA with 12-hour light/
dark cycle.
Immunohistochemistry studies
In the present study, three male adult mice from each group, wt
and R6/2 and five male adult mice from wt and SSTR1/5
2/2
mice were used. 30 mm thick coronal brain sections were cut on
Leica vibratome. Immunostaining was performed on free-floating
sections using the avidin–biotin peroxidase Vectastain ABC kit as
described previously [45,73,75]. Briefly, brain sections were
incubated with 0.3% hydrogen peroxide followed by incubation
with 0.02% Triton X-100. Following three washes, sections were
incubated with 5% NGS for 1 h at room temperature (RT) and
followed by overnight incubation with specific primary antibodies
against rabbit-anti-SSTR1-5 (1:500), rabbit-anti-SST (1:600),
mouse anti-DARPP-32 (1:250), mouse anti-NMDAR-1,
NMDAR-2A, NMDAR-2B and calbindin D-28K (1:500) and
rabbit anti-bNOS (1:400) in 1% NGS at 4uC in humid
atmosphere. The sections were incubated with the biotinylated
secondary antibodies; goat-anti-rabbit to detect SSTRs, SST, and
bNOS and goat anti-mouse to detect DARPP-32, calbindin and
NMDARs and followed by incubation in ABC complex for
30 min. The final color was developed by adding a mixture
containing 0.001% hydrogen peroxide and 0.2 mg/ml of 3,3-
diaminobenzidine (DAB) for 3–4 min in 50 mM Tris buffer.
Sections were washed in PBS, mounted onto slides and viewed and
photographed under Leica microscope attached with the Retiga
2000R camera.
Western blot analysis
Striatal tissues isolated from R6/2 or SSTR1/5
2/2 mice and
respective wt brains were homogenized in homogenizing buffer
containing (62.5 mM Tris-HCl, 50 mM dithiothretiol [DTT],
10% glycerol, 2% SDS). 15 mg of total protein was fractioned by
electrophoresis on 10% SDS polyacrylamide gel, transferred onto
0.2 mm-nitrocellulose membrane. The membrane was blocked
with 5% non-fat dried milk at RT for 1 h and incubated overnight
at 4uC with specific primary antibodies against– SSTRs1-5,
NMDARs, bNOS (1:600), SST, enkephalin, synapsinIIa, calpain,
calcineurin, calbindin, phospho and total ERK1/2, PI3K (1:1000),
DARPP-32 (1:250) and PKC-a (1:500). Following three subse-
quent washes, the membrane was incubated with peroxidase
conjugated goat anti-rabbit or a goat anti-mouse secondary
antibody at RT for 1 h. The bands were detected using
chemiluminescence reagent and images were taken using an
Alpha Innotech FluorChem 8800 (Alpha Innotech Co., San
Leandro, CA) gel box imager. b-actin was used as the
housekeeping protein for loading control. The bands intensity
was quantified using densitometric analysis and the changes in
protein expression were calculated as the ratio of band of interest
and the density of b-actin.
Quantitative analysis
Quantitative analysis on brain sections was performed using
NIH Image J software as described earlier [45]. Neurons were
considered immunoreactive if the labeling of their cell bodies was
distinctly higher than the background staining obtained in the
presence of pre-absorbed or in the absence of primary antibodies.
For quantitative analysis five mice were taken from wt, SSTR1/
5
2/2 mice and three for wt and R6/2 mice. 12–15 randomly
selected areas from 6–7 sections from individual mouse brain were
used for neuronal counting. Since our immunohistochemical
studies provide semiquantitative analysis of immunoreactivity in
R6/2 or SSTR1/5
2/2 and respective wt mice we took all the
possible precaution to keep our experimental conditions consistent
in all aspects, i.e., incubation timings with antibodies (18 h) and 3,
3-diaminobenzidine for the final color development (4 mins).
Statistical analysis
Data are presented as percentage changes in neuronal
population for positive immunoreactivity from 6–7 brain sections
per mice. Total of (6000–6500) neurons were counted in each
condition. Bars represent the mean 6 SEM (n=3 for R6/2 and
n=5 for SSTR1/5
2/2). Statistical comparison between wt and
R62 (n=3) and wt and SSTR1/5
2/2 (n=5) mice were analyzed
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CA) was used to perform all the statistical analysis.
Supporting Information
Figure S1 Quantitative analysis of SSTR postive neurons for
receptor specific changes in SSTR1/5
2/2 and R6/2 mice strains.
Note receptor specific changes in the numbers of SSTR1–5
positive neurons in SSTR1/5
2/2and R6/2 mice compared to the
respective wt. Data presented as mean 6 SD for neuronal
quantification (SSTR1/5
2/2, n=5 and R6/2 mice, n=3) in
comparison to wt mice brain, *P,0.05, ** P,0.01.
(TIF)
Figure S2 Downstream signalling pathways are differentialy
regulated in R6/2 and SSTR1/5
2/2 mice. Tissue lysate prepared
from striatum of R6/2 and SSTR1/5
2/2 mice brain was
fractionated on 10% SDS PAGE and membrane was blotted for
total and phosphorylated ERK1/2 and PI3K and PKC-a. The
status of p-ERK1/2 is not changed in R6/2 and SSTR1/5
2/2
mice striatum (a). Note the decreased expression level of PI3K
(110 kDa) in R6/2 mice whereas SSTR1/5
2/2 mice brain
exhibited increased PI3K expression (b). In contrast PKC-a
(80 kDa) decreased in R6/2 and SSTR1/5
2/2 mice brain (c).
Data presented as mean 6 SD (SSTR1/5
2/2, n=5 and R6/2
mice, n=3) in comparison to wt mice brain, *P,0.05, ** P,0.01,
***P,0.001.
(TIF)
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